Ozempic is generally safe when prescribed and monitored by a physician, but it is not FDA-approved for weight loss. The FDA approved Ozempic specifically for managing type 2 diabetes in adults. A higher dose of the same active ingredient, semaglutide, is sold under the brand name Wegovy and is the version approved for chronic weight management. When people use Ozempic “off-label” for weight loss, they’re taking a diabetes drug at a lower dose than what was tested and approved for that purpose.
Why Ozempic and Wegovy Are Not the Same
Both Ozempic and Wegovy contain semaglutide, but at different doses and with different approved uses. Ozempic is available in 0.5 mg and 1 mg weekly injections for blood sugar control. Wegovy goes up to 2.4 mg weekly and was tested specifically in people with obesity (a BMI of 30 or higher) or overweight (BMI of 27 or higher) with at least one weight-related condition like high blood pressure or high cholesterol.
This distinction matters because the safety data for weight loss comes primarily from trials using the higher Wegovy dose. If your goal is weight loss rather than blood sugar management, Wegovy is the version that has been studied for that purpose, and it’s the one your insurance is more likely to cover for a weight management indication.
Common Side Effects
The most frequent side effects are gastrointestinal: nausea, vomiting, diarrhea, constipation, and stomach pain. These tend to be worst during the first few weeks and during dose increases. Most people find that symptoms ease as their body adjusts, which is why prescribers start at a low dose and increase gradually over several months.
Nausea is the side effect most people notice first. Eating smaller meals, avoiding high-fat foods, and eating slowly can reduce it. For many users, these digestive symptoms are manageable but not trivial. They’re the most common reason people stop taking the medication.
The Boxed Warning: Thyroid Tumors
Ozempic carries the FDA’s most serious type of warning, a boxed warning, about the risk of thyroid C-cell tumors. In rodent studies, semaglutide caused thyroid tumors at doses similar to those used in humans. Whether this happens in people remains unknown. The FDA label states plainly: “It is unknown whether OZEMPIC causes thyroid C-cell tumors, including medullary thyroid carcinoma, in humans.”
Because of this uncertainty, Ozempic is contraindicated if you or a close family member have a history of medullary thyroid carcinoma or a genetic condition called Multiple Endocrine Neoplasia syndrome type 2. If neither applies to you, the risk is considered theoretical but worth knowing about. Symptoms to watch for include a lump in the neck, difficulty swallowing, or persistent hoarseness.
Pancreatitis Risk
Inflammation of the pancreas is a known risk with this class of drugs. The UK’s medicines regulator has received nearly 1,300 reports of pancreatitis in people taking GLP-1 drugs between 2007 and late 2025, including 19 deaths. Patient information leaflets for drugs in this class note that acute pancreatitis may affect up to 1 in 100 users.
The challenge is that early pancreatitis symptoms, such as severe stomach pain radiating to the back, nausea, and vomiting, overlap with the common gastrointestinal side effects of the drug itself. That overlap can delay diagnosis. If you develop sudden, intense abdominal pain that doesn’t go away, particularly pain that spreads to your back, that warrants urgent medical attention. A history of pancreatitis is considered a contraindication.
Gallbladder and Kidney Concerns
Rapid weight loss, regardless of the method, increases the risk of gallstones. Semaglutide accelerates this risk because it can produce significant weight loss over a relatively short period. People with existing gallbladder disease are generally not good candidates for the medication.
Kidney issues are also on the radar. The primary concern is dehydration: semaglutide can cause enough nausea, vomiting, and diarrhea to deplete your fluid levels, which may in turn stress the kidneys. Staying well-hydrated is more important on this medication than most people realize, especially during the early weeks when GI symptoms are at their peak.
Muscle Loss Is a Real Trade-Off
One of the less-discussed safety concerns isn’t an adverse event in the traditional sense. It’s the amount of muscle you lose alongside fat. In the STEP-1 trial, participants lost an average of 15.3 kg (about 34 pounds) on semaglutide, but roughly 6.9 kg of that, about 45%, came from lean mass rather than fat. That is nearly double the proportion typically expected during weight loss, where a general rule of thumb predicts that about one-quarter of lost weight comes from lean tissue.
Losing that much muscle can affect your metabolism, physical strength, bone density, and long-term ability to maintain weight loss. This is why resistance training and adequate protein intake are strongly emphasized for anyone on semaglutide. The drug produces weight loss, but the quality of that weight loss depends significantly on what you do alongside it.
Cardiovascular Benefits
On the positive side of the safety ledger, the SELECT trial provided strong evidence that semaglutide at the 2.4 mg dose (the Wegovy dose) reduced major cardiovascular events by 20% compared to placebo. This trial enrolled people who were overweight or obese with existing heart disease but without diabetes, and it tracked outcomes including heart attacks, strokes, and cardiovascular death. This was a meaningful enough finding that it reshaped how many cardiologists think about the drug’s role beyond weight loss alone.
Mental Health and Suicidal Thoughts
Early concerns about a possible link between GLP-1 drugs and suicidal thoughts prompted an extensive FDA investigation. The agency analyzed 91 placebo-controlled trials covering nearly 108,000 patients and conducted a separate real-world study of over 2.2 million users. Neither analysis found an increased risk of suicidal behavior, intentional self-harm, depression, anxiety, or other psychiatric events. Based on this review, the FDA in 2024 requested that manufacturers remove the suicidal ideation warning from the labels of Wegovy, and related medications.
Pregnancy
Semaglutide should not be used during pregnancy. Because the drug stays in your system for an extended period after your last injection, the FDA recommends stopping Ozempic at least two months before a planned pregnancy. If you’re of reproductive age and considering the medication, this washout timeline is important to factor into your planning.
Who Should Not Take It
Beyond the contraindications already mentioned, semaglutide is not appropriate for people with a known allergy to the drug or its components, those with significant gastroparesis (a condition where the stomach empties very slowly), or those with active gallbladder disease. It has not been studied in combination with other weight loss drugs and is not approved for use in children under 12.
For people without these contraindications, semaglutide has a well-characterized safety profile built from large clinical trials and years of real-world use. The risks are real but manageable for most users when the drug is prescribed appropriately and monitored over time. The most important safety factor may be the simplest one: using the right version of the drug for the right indication, under medical supervision, rather than sourcing it informally or using it without follow-up.